Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02180711 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02180711 · ClinicalTrials.gov record · last posted 2026-07-08

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

StatusActive, Not Recruiting
PhasePhase 1/2
Started2014-12-29
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL

Amendment record 20 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 20 times since 2014-07-01; most recent amendment 2026-06-15. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-03-25
Status change Recruiting→Active, Not Recruitingv10
2018-02-12
Status change Active, Not Recruiting→Recruitingv6
2016-12-01
Status change Recruiting→Active, Not Recruitingv4
2014-10-29
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT02180711
Lead Sponsor Acerta Pharma BV
Collaborators: AstraZeneca
Conditions Non Hodgkin Lymphoma
Enrollment 113 participants
Start Date 2014-12-29
Primary Completion 2023-08-25 (estimated)
Study Completion 2028-12-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-08